Regulatory Compliance

Providence, R.I. – September 21, 2026 -- Nabsys 2.0, LLC has published the first study combining CRISPR/Cas9 with its proprietary Electronic Genome Mapping (EGM) technology, demonstrating a method to both evaluate CRISPR/Cas9 activity and direct EGM to target specific genomic regions rather than only genome-wide analysis.

The preprint, titled 'CRISPR/Cas9 Optimization Using Electronic Genome Mapping: Potential Role for Studying Human Genetic Disease,' was led by John F. Thompson, Ph.D., Principal Application Scientist at Nabsys, and posted on bioRxiv.

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.

Two of three evaluable patients hit 80% tumor shrinkage in dose-escalation trial

In the prospective, investigator-initiated trial (ChiCTR2500107346), five patients with heavily pretreated, guideline-exhausted brain metastases completed treatment. Of the three with measurable disease, two achieved partial responses and one achieved stable disease. As of the company's September 2026 follow-up, the two responders have survived more than 11 and 13 months, respectively, since their first MT027 dose, and all three evaluable patients remain alive.

Jerusalem – September 21, 2026 -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule after its American Depositary Shares closed at or above that threshold for 19 consecutive business days, Nasdaq Listing Qualifications confirmed in a September 18, 2026 letter.

Nasdaq closes compliance matter after ADS price clears threshold for 19 sessions

The closing bid price of Scinai's ADSs met or exceeded $1.00 per share from August 21, 2026 through September 17, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq had first flagged the deficiency on March 12, 2026, after the ADSs failed to maintain the $1.00 minimum over the prior 30 consecutive business days.

CEO says resolution shifts focus to CDMO commercial execution

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai,

Bridgewater, N.J. – September 21, 2026 -- The U.S. Food and Drug Administration has accepted Insmed Incorporated's supplemental New Drug Application (sNDA) for full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease, granting Priority Review with a PDUFA target action date of January 28, 2027.

FDA sets January 28, 2027 decision date under Priority Review

The Priority Review designation applies to therapies that could offer significant improvement in safety or efficacy for serious conditions. Insmed said full approval would allow ARIKAYCE, administered via PARI Pharma's Lamira Nebulizer System, to reach patients earlier in their disease course, including newly diagnosed cases and those with recurrent infections.

Germantown, Md. – September 21, 2026 -- The U.S. Food and Drug Administration has granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, the technology underlying the company's first commercial product, PAPZIMEOS, approved in August 2025 for recurrent respiratory papillomatosis (RRP) in adults.

FDA designation opens accelerated pathway for future AdenoVerse cancer programs

The designation allows Precigen to leverage manufacturing and preclinical data generated for PAPZIMEOS to support future marketing applications for other AdenoVerse-based candidates, reducing duplicative development work. It also grants the company earlier and more frequent FDA engagement and allows regulators to consider prior manufacturing inspections when reviewing future applications.

Delray Beach, Fla. – September 21, 2026 -- The global rubber process oil (RPO) market is set to expand from $3.30 billion in 2026 to $3.94 billion by 2031, growing at a compound annual growth rate of 3.6%, according to a new report from MarketsandMarkets.

Tire manufacturing drives largest share of oil demand

The tires application segment is projected to register the highest growth at 4.7% CAGR and remains the largest consumer of RPO by value. Manufacturers rely on process oils to balance flexibility, durability, and processing efficiency across passenger, commercial, and specialty tire production. Rising replacement-tire demand and evolving fuel-efficiency standards are reinforcing this consumption base.

Kunshan – September 21, 2026 -- Arctech has been awarded a Silver Medal in the 2026 EcoVadis Sustainability Rating, placing the solar tracker maker among the top 15% of companies assessed by EcoVadis worldwide.

EcoVadis scores companies across four sustainability pillars

The rating agency evaluates firms on Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, ranking medal recipients by percentile against all companies assessed globally over the prior 12 months. Arctech's Silver Medal corresponds to the top 15% tier.

Arctech spent RMB 4.3629 million on environmental protection in 2025

That figure, approximately US$651,000, funded initiatives tied to the company's environmental performance improvements. Its self-owned photovoltaic power stations generated more than 34 million kWh of electricity, covering 24% of Arctech's total electricity consumption.

Aachen, Germany – September 21, 2026 -- Grünenthal has agreed to acquire Bayer AG's oncology drug Stivarga® (regorafenib) for up to €375 million, adding an oral cancer treatment sold in more than 90 markets to its portfolio.

Grünenthal expects Stivarga to add up to €100 million to EBITDA in 2027

The German pharmaceutical company said the acquisition is immediately accretive to its business, with an estimated positive impact on consolidated EBITDA of approximately €100 million for the year ending December 31, 2027. That projection assumes the deal closes by the end of 2026 or early 2027 and includes a full year of consolidation.

Stockholm – September 21, 2026 -- Telefonaktiebolaget LM Ericsson repurchased Class B shares between September 14 and September 18, 2026, under its ongoing SEK 15,000,000,000 buyback program, lifting the company's treasury stock holding to 108,018,663 Class B shares.

Ericsson's buyback program targets up to SEK 15 billion through March 2027

The repurchase activity forms part of a program Ericsson announced on April 16, 2026, running from April 23, 2026, through March 31, 2027 at the latest. The initiative is structured under the EU's Market Abuse Regulation (No 596/2014) and the accompanying Safe Harbour Regulation (Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016), ensuring the transactions comply with European market conduct rules.

Boston – September 21, 2026 -- Global M&A value climbed 15% year over year in the first eight months of 2026, exceeding the ten-year average by 11%, according to a new report from Boston Consulting Group (BCG). The number of megadeals worth $10 billion or more rose to 37 from 24 a year earlier, surpassing 2021's record of 32.

Megadeal surge masks a narrower recovery below the top of the market

Transactions valued at $1 billion or more are running above longer-term norms, but deal volume for small-cap and midcap transactions remains below historical levels even before inflation adjustments. BCG's M&A Sentiment Index rose to 83 from 79 at the start of the year, still well below its long-term average of 100.